Treatment of HCV infected patients and renal disease

Area of Science:

• Nephrology
• Infectious Diseases
• Hepatology

Background:

• Hepatitis C virus (HCV) infection is highly prevalent in patients with end-stage renal disease (ESRD).
• HCV is frequently associated with glomerulonephritis, hemodialysis patients, and renal transplant recipients.
• Prevalence of HCV antibodies in hemodialysis patients ranges from 5-70%, varying by geographic location.

Purpose of the Study:

• To review the prevalence, risk factors, transmission, and treatment of Hepatitis C virus in patients with end-stage renal disease.
• To highlight the importance of pre-transplant antiviral therapy in renal transplant recipients.

Main Methods:

• Literature review of studies on Hepatitis C virus in end-stage renal disease patients.
• Analysis of factors associated with HCV prevalence in hemodialysis patients.
• Review of transmission routes and treatment strategies for HCV in this population.

Main Results:

• Risk factors for HCV in hemodialysis patients include age, blood transfusions, tattoos, drug use, duration of dialysis, hospitalizations, multiple dialysis units, and kidney transplant.
• Nosocomial transmission of HCV in dialysis units can occur due to breaches in infection control and shared equipment.
• Interferon treatment post-renal transplant increases rejection rates, suggesting pre-transplant administration is preferable.

Conclusions:

• Hepatitis C virus poses a significant challenge in end-stage renal disease management.
• Strict adherence to infection control measures is crucial to prevent nosocomial HCV transmission in dialysis units.
• Antiviral treatment for Hepatitis C virus should be considered before renal transplantation to optimize outcomes.